

22 January 2026

## Botanix Webinar – 27 January – Registration Information

**Philadelphia PA and Phoenix AZ 22 January 2026:** Commercial dermatology company, Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (ASX:BOT, “Botanix” or “the Company”), announces that registration is open for an investor webinar hosted by Executive Chairman Vince Ippolito, Chief Executive Officer Dr Howie McKibbon and US Chief Financial Officer Chris Lesovitz. The webinar will share comprehensive insights into the Company’s Quarterly Activity Report and 4C Quarterly Cash Flow Report and provide an update for *Sofdra*® (sofpironium) topical gel, 12.45%.

The webinar will be held on Tuesday 27 January 2026, at 10.30 am AEDT (Sydney/ Melbourne)/7.30 am AWST (Perth). Interested participants **must register before the webinar using the link below**. Dial-in details will be sent in return.

### Webinar Details

**Date:** 27 January 2026

**Time:** 10.30 am AEDT (Sydney/Melbourne), 7.30 am AWST (Perth)

**To register:** [https://us06web.zoom.us/webinar/register/WN\\_XOM7QZfiRhp3nJ8mwGugg](https://us06web.zoom.us/webinar/register/WN_XOM7QZfiRhp3nJ8mwGugg)

**Dial-in details:** Will be sent to you directly upon registration

Release authorised by the Botanix Board.

### About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US), which has received FDA approval for *Sofdra*, its product for the treatment of primary axillary hyperhidrosis. *Sofdra* is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel, safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more please visit: <http://www.botanixpharma.com/>

For more information, please contact:

**General enquiries**

Corporate Communications  
Botanix Pharmaceuticals  
P: +61 8 6555 2945  
[investors@botanixpharma.com](mailto:investors@botanixpharma.com)

**Investor enquiries**

Hannah Howlett  
P: +61 4 5064 8064  
[investors@botanixpharma.com](mailto:investors@botanixpharma.com)

**Media enquiries**

Haley Chartres  
H^CK  
P: +61 423 139 163  
[haley@hck.digital](mailto:haley@hck.digital)

**Cautionary Note on Forward-Looking Statements**

Forward-looking statements can generally be identified by the use of forward-looking words such as, "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target" "outlook", "guidance" and other similar expressions and include, but are not limited to, plans and prospects for the Company, the Company's strategy, future operations, the expected timing and/or results of regulatory approvals and prospects of commercialising product candidates or research collaborations with its partners, including in Japan, the outcome and effects of *Sofdra*® and the market for *Sofdra*. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. The forward-looking statements contained in this Presentation are not indications, guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Botanix, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. Investors should consider the forward-looking statements contained in this Presentation in light of those disclosures and not place undue reliance on such statements. Except as required by law or regulation, Botanix undertakes no obligation to update forward-looking statements.

## **Sofdra Important Safety Information & Indication**

### **Indication**

*Sofdra* (sofipironium) topical gel, 12.45% is a prescription anticholinergic medicine used on the skin (topical) to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children 9 years of age and older.

### **IMPORTANT SAFETY INFORMATION**

***Sofdra* is for use on the skin in the underarm area only. Wash your hands right away after you apply *Sofdra*. Do not touch your underarms after applying *Sofdra*. *Sofdra* is flammable. Avoid heat and flame while applying *Sofdra*.**

### **Who should not use *Sofdra*?**

Do not use *Sofdra* if you have certain medical conditions that can be made worse by taking an anticholinergic medicine such as glaucoma, severe ulcerative colitis (UC) or certain other serious bowel problems associated with severe UC, myasthenia gravis, and Sjogren's syndrome.

### **What should I tell my healthcare provider before using *Sofdra*?**

- **Tell your healthcare provider about all of your medical conditions**, including bladder or kidney problems, problems passing urine, if you are pregnant or breastfeeding, or plan to become pregnant or breastfeed. It is not known if *Sofdra* will harm your unborn baby or pass into your breast milk.
- **Tell your healthcare provider about all the medicines you take**, including prescription and over-the-counter medicines, especially any anticholinergic medicines.

### **What are possible side effects of *Sofdra*?**

#### **Serious side effects may include:**

- **Blurred vision.** Stop using *Sofdra*, call your healthcare provider right away, and do not drive or operate machinery or do hazardous work until your vision is clear.
- **New or worsened urinary retention.** Stop using *Sofdra* and call your healthcare provider right away if you experience difficulty urinating, urinating frequently, urination in a weak stream or drips, full bladder or difficulty emptying your bladder.

**The most common side effects of *Sofdra* include** dry mouth; blurred vision; pain, redness, swelling, itching, and irritation in the underarm area; dilation of the pupils of your eyes (mydriasis); and problems with urination. These are not all of the possible side effects of *Sofdra*. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088. You may also report side effects to Botanix at 1-866-763-6337.

**Keep *Sofdra* and all medicines out of the reach of children.**